Clinical trials: Active Rheumatoid Arthritis
- Condition Active Rheumatoid Arthritis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Juvenile Rheumatoid Arthritis
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept).
- Trial name
- NCT00095173
- Testing
- Abatacept
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 214 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Juvenile Rheumatoid
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
- Trial name
- NCT00652925
- Testing
- Celecoxib, Naproxen
- Where
- 58 sites in United States, Belgium and 13 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Arthritis, Juvenile Rheumatoid
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis
- Trial name
- NCT00807846
- Testing
- Celecoxib, Naproxen
- Where
- 39 sites in United States, Chile and 8 more
- Volunteers
- 201 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients.
- Trial name
- NCT00195338
- Testing
- etanercept
- Where
- Luxembourg
- Volunteers
- 25 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)
This 14-week non-interventional study will observe patients with rheumatoid arthritis (RA) who are being treated with infliximab for the first time, in order to learn about their disease characteristics.
- Trial name
- REMARK (NCT00705289)
- Testing
- Infliximab
- Volunteers
- 728 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
This is a single-arm, multi-center, prospective cohort study (post-marketing observational study). The observation period for each participant is 48 weeks.
- Trial name
- NCT01346488
- Volunteers
- 2,088 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Active Rheumatoid Arthritis
Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870
The objective of this study is to evaluate the safety and efficacy of CDP870 self-injection administered for 24 weeks or longer in subjects who are participating in the long-term treatment study (Study 275-08-002 or Study…
- Trial name
- NCT02586246
- Testing
- CDP870
- Where
- 15 sites in Japan
- Volunteers
- 86 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)
This observational study will explore the Swedish national population of patients with rheumatoid arthritis (RA) on infliximab maintenance therapy in order to identify patients who may be eligible for a dose reduction study.
- Trial name
- REQUEST (NCT00741104)
- Testing
- Infliximab
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Systemic Juvenile Idiopathic Arthritis With Active Flare
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.
- Trial name
- β-SPECIFIC 2 (NCT00889863)
- Testing
- canakinumab
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children
This postmarketing surveillance study will evaluate the safety profile of Enbrel (etanercept) in an Indian population. It will provide surveillance on a currently approved indication for Enbrel of reducing symptoms and inhibiting…
- Trial name
- NCT00484809
- Testing
- Enbrel (Etanercept)
- Volunteers
- 100 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
Study Evaluating the Efficacy and Safety of Etanercept
To assess the efficacy of etanercept 25 mg administered subcutaneously twice-weekly for 12 weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or inappropriate.
- Trial name
- NCT00546533
- Testing
- Etanercept
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer